

UNIVERSIDADE ESTADUAL DE CAMPINAS
SISTEMA DE BIBLIOTECAS DA UNICAMP
REPOSITÓRIO DA PRODUÇÃO CIENTÍFICA E INTELLECTUAL DA UNICAMP

Versão do arquivo anexado / Version of attached file:

Versão do Editor / Published Version

Mais informações no site da editora / Further information on publisher's website:

https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X1996000200026

DOI: 10.1590/S0004-282X1996000200026

Direitos autorais / Publisher's copyright statement:

©1996 by Associação Arquivos de Neuro-Psiquiatria. All rights reserved.

DIRETORIA DE TRATAMENTO DA INFORMAÇÃO

Cidade Universitária Zeferino Vaz Barão Geraldo

CEP 13083-970 – Campinas SP

Fone: (19) 3521-6493

<http://www.repositorio.unicamp.br>

BIOLOGY OF THE REPAIR OF CENTRAL NERVOUS SYSTEM DEMYELINATED LESIONS

AN APPRAISAL

L.A.V. PEIREIRA*, M.A. CRUZ-HÖFLING**, M.S.J. DERTKIGIL***, D.L. GRAÇA****

ABSTRACT - The integrity of myelin sheaths is maintained by oligodendrocytes and Schwann cells respectively in the central nervous system (CNS) and in the peripheral nervous system. The process of demyelination consisting of the withdrawal of myelin sheaths from their axons is a characteristic feature of multiple sclerosis, the most common human demyelinating disease. Many experimental models have been designed to study the biology of demyelination and remyelination (repair of the lost myelin) in the CNS, due to the difficulties in studying human material. In the ethidium bromide (an intercalating gliotoxic drug) model of demyelination, CNS remyelination may be carried out by surviving oligodendrocytes and/or by cells differentiated from the primitive cell lines or either by Schwann cells that invade the CNS. However, some factors such as the age of the experimental animals, intensity and time of exposure to the intercalating chemical and the topography of the lesions have marked influence on the repair of the tissue.

KEY WORDS: toxic demyelination, remyelination, central nervous system, peripheral nervous system.

Biologia da reparação de lesões desmielinizantes do sistema nervoso central: uma avaliação

RESUMO - A integridade da bainha de mielina é fornecida pelos oligodendrócitos e pelas células de Schwann, no sistema nervoso central (SNC) e no sistema nervoso periférico, respectivamente. O fenômeno de desmielinização refere-se à remoção das bainhas de mielina de axônios e este fato é característico na esclerose múltipla, a doença desmielinizante do SNC mais comum no homem. Muitos modelos experimentais têm sido utilizados para o estudo da biologia da desmielinização e remielinização no SNC, face à dificuldade de estudo de material humano. No modelo experimental da droga intercalante, gliotóxica, brometo de etídio, a remielinização do SNC pode ser efetuada por oligodendrócitos sobreviventes à lesão e/ou oriundos de diferenciação de linhagens celulares mais primitivas e por células de Schwann que invadem o SNC. No entanto, fatores como a idade dos animais, a intensidade, e o tempo de exposição ao agente intercalante e a topografia da lesão influenciam significativamente a reparação da lesão.

PALAVRAS-CHAVE: desmielinização tóxica, remielinização, sistema nervoso central, sistema nervoso periférico.

The central nervous system (CNS) develops from a thickened area of the embryo ectoderm, the neural plate. The neural tube formation and the neural crest development will respectively give rise to the CNS and

Study carried out in the Department of Histology and Embryology (DHE), Institute of Biology (IB), State University of Campinas (UNICAMP) and Department of Pathology (DP), Health Science Center (CCS), Federal University of Santa Maria (UFSM): * Assistant Professor DHE/IB/UNICAMP; ** Associate Professor DHE/IB/UNICAMP; *** Graduate Student of Medical Sciences/UNICAMP; **** Professor of Pathology DP/CCS/UFSM. Aceite:9-janeiro-1996.

Dr. Luís Antônio Violin Pereira - Department of Histology and Embryology, IB/UNICAMP - P.O.Box 6109 - 13083-970 Campinas SP - Brazil. FAX 55 192 39 3124.

most of the peripheral nervous system (PNS). Thus histologically the nervous tissue of the CNS is made up of neurons and glial cells from a single layer of proliferating neural epithelium or by cells of the primitive neural tube (for details see Moore²⁰; Pereira & Graça²⁴) and a non-collagenic extracellular matrix³.

Raff et al²⁶ and Raff²⁷ defined the neuroglia according to the expression of cellular antigens along their fetal development, using immunocytochemical methods. Astrocytes may be classified into two distinct classes: Type I (former protoplasmic), RAN-2⁺ and Type II (former fibrous) A2B5⁺. Type II astrocytes assist interfascicular oligodendrocytes in the formation and maintenance of the myelin sheath and in saltatory conduction²⁷. Interrelationships between Type II astrocytes and oligodendrocytes (GC⁺) come from a common embryonic origin, the O-2A cell²⁷.

In the CNS oligodendrocytes put many layers of their cytoplasmic membrane around one or more axons, forming a spiralled structure, the myelin sheath under the form of short tubes named internodes¹. In the PNS myelin sheath formation is made up by Schwann cells. Each Schwann cell forms one 1 mm long internode in a single axon composed of up to 300 concentric lamellae¹. Oligodendrocytes form similar segments although they extend cytoplasmic processes that may myelinate many axons simultaneously, in some cases up to two hundred¹⁰. This fact and the proliferation potentialities of Schwann cells explain the larger repair capacity of demyelinated lesions in the PNS.

DEMYELINATION/REMYELINATION


The phenomenon of demyelination consists of the removal of myelin sheaths from normal CNS and PNS axons usually with perivascular infiltration of small lymphocytes, red blood cells and large mononuclear cells²⁹. Such myelin loss is frequently referred as primary demyelination³ and must be differentiated from degeneration of myelin sheaths following axonal degeneration, known as Wallerian degeneration.

Many experimental models have been used to study the biology of primary demyelination and remyelination that take part in spontaneous CNS diseases. Those models seek to mimic demyelinating pathologies and to search for physiological features of those diseases including the behavior of glial cells involved with repair processes after the action of harmful agents. Among these demyelinating CNS diseases, multiple sclerosis (MS) and distemper, in humans and canines respectively, are the most striking, being the most marked histological feature of such disorders the presence of persistent demyelinated areas which consistently fail to remyelinate and are responsible for the symptoms of the disease.

Inoculation of lytic viruses that infect oligodendrocytes, such as Theiler's virus¹⁸; induction of immunologic reactions against cells that express viral antigens, such as those of Semliki Forest virus¹⁵; induction of *in vivo* immunological reactions by intradermal inoculation of emulsified brain¹⁷; *in vitro* addition of myelinotoxic EAE (experimental allergic encephalomyelitis) serum¹⁶; systemic administration of toxic substances such as cuprizone¹⁹ and hypocholesterolemic drugs³²; local injection of either myelinotoxic or gliotoxic agents such as lysolecithin⁶, 6-aminonicotinamide⁴ and ethidium bromide (EB)^{5,9,12,13,23,31,34}, are among the experimental models which have been developed in order to clarify the cellular processes of demyelination and remyelination.

As in individuals suffering of MS there is a persistent failure in the repair of lost myelin sheaths, the viewpoint that remyelination did not occur in the CNS was sustained for many years. However in 1961, Bunge et al.⁷ firstly reported CNS remyelination after demyelination following cerebral fluid barbotage in the cat. Albeit the remyelinating process is viable, it depends upon factors as the intensity, the exposition time to the demyelinating agent¹⁰ as well as the CNS areas involved²³. In the EB model of demyelination when the lesion is inflicted to the spinal cord of Wistar rats, remyelination may be accomplished either by surviving oligodendrocytes over the edges of the lesions or Schwann cells that invade the CNS along subpial and perivascular areas (Fig 1 to 4)^{9,13}. When EB is injected into the brain stem of Wistar rats, remyelinating-oligodendrocytes- repair myelin sheaths chiefly around the periphery of the lesions and Schwann cells remyelinate axons also in places other than subpial and perivascular areas^{23,25}.

Although remyelination is well recognized both in experimental models and spontaneous diseases the origin of oligodendrocytes and Schwann cells remains a controversial issue. Three hypothesis are proposed for the presence of remyelinating oligodendrocytes: 1) they would be surviving cells from the edges of the lesions in MS cases³⁰; 2) oligodendrocytes would be able of generating remyelinating daughter-cells¹⁹, although the absence of morphological demonstration of oligodendrocyte mitosis in adult individuals, is an intriguing feature; 3) oligodendrocytes might come from the differentiation of the adult O-2A lineage cells, once autoradiographic



Figs 1 to 4: EB model of demyelination of the CNS. 1. Normal white matter of the spinal cord in an adult Wistar rat: astrocyte (A), oligodendrocyte (O); myelinated axons (*) 4300X; 2. demyelinated axons (*) separated by processes from an astrocyte (A) 4300X; 3. Oligodendrocyte (O) remyelination of demyelinated axons. There are irregularly packed myelin lamellae (arrowhead) and the presence of astrocytic processes (A) closely related to the new sheaths. 4300 X. 4. Schwann cell (S) remyelination of demyelinated axons. Myelin sheaths show loosely packed myelin lamellae (arrow). Some interstitial collagen fibres (arrowhead) about Schwann cells basal laminae. 4300 X. IB. UNICAMP.

experiments show poor oligodendrocyte proliferation in adult mice²¹. Oligodendroglial replacement in adult animals is being studied by immunocytochemical identification of the adult O-2A lineage cells and to find out which stimuli trigger the proliferation and differentiation of cells of such lineage constitute the goal of numerous investigations³³. However the most relevant feature is that oligodendrocytes may be a replacement source since profuse astrocytic gliosis, observed in most lesions of the CNS, does not hinder remyelination²².

On the other hand, the presence of myelinating Schwann cells in the CNS has been depicted in normal²⁸ as well as in several demyelinating processes related to human diseases such as MS¹⁴ and many of the experimental models mentioned above. The way and stimulus for the migration of Schwann cells into demyelinating lesions in the spinal cord has been comprehensively discussed by Graça⁹. The origin of Schwann cells in those lesions appears to be related to blood vessels, pial and dorsal nerve root^{9,11}.

Although remyelination is a fact in most experimental models of demyelination, it is necessary to understand the mechanisms that interfere with that function in MS lesions. One limiting factor could be the gliosis⁴ made up by Type I astrocytes although oligodendrocyte remyelination in gliotic areas in the brain of Wistar rats²³ and humans² has been consistently reported. Thus, astrocytosis *per se* can not be blamed for the lack of remyelination^{23,25}. The main problem seems to be the lack of appropriate stimuli for the differentiation of cells from the O-2A lineage. Astrocytic gliosis and the integrity of the blood brain barrier, on the other hand, could interfere with the CNS invasion of the Schwann cells²³.

Acknowledgements - This study was benefited in part by a Grant-in Aid for Scientific Research (project number 93/4994-5) from FAPESP (São Paulo, Brazil). The authors wish to thank Mrs. Adriane S.Sprogis, Antonia F. Lima (UNICAMP) and Iara E. Flores (UFSM) for the technical assistance.

REFERENCES

1. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Molecular biology of the cell. Ed. 3, New York:Garland, 1994.
2. Allen IV, Kirk J. Demyelinating diseases. In Adams JH, Duchen LW (eds). Greenfield's neuropathology. London:Edward Arnold, 1992:447-520.
3. Bertolotto A, Rocca G, Schiffer D. Chondroitin 4-sulfate proteoglycan forms an extracellular network in human and rat central nervous system. *J Neurol Sci* 1990;100:113-123.
4. Blakemore WF. Remyelination by Schwann cells of axons demyelinated by intraspinal injection of 6-aminonicotinamide in the rat. *J Neurocytol*. 1975;4:745-757.
5. Blakemore WF. Myelination, demyelination and remyelination in the CNS. In Cavanagh JB, Smith WT (eds). Recent advances in neuropathology. Edinburgh:Churchill Livingstone, 1982:53-81.
6. Blakemore WF, Eames RA, Smith KJ, McDonald WI. Remyelination in the spinal cord of the cat following intraspinal injections of lysolecithin. *J Neurol Sci* 1977;33:31-43.
7. Bunge M, Bunge RP, Ris, H. Ultrastructural study of remyelination in an experimental lesion in adult cat spinal cord. *J Biophys Biochem Cytol* 1961;10:67-94.
8. Eng LF, Yu ACH, Lee YL. Astrocytic response to injury. *Progr Brain Res* 1992;94:353-365.
9. Graça DL. Investigation into ethidium bromide induced demyelination in the central nervous system. PhD Thesis, University of Cambridge. Cambridge, 1986.
10. Graça DL. Mielinização, desmielinização e remielinização no sistema nervoso central. *Arq Neuropsiquiatr* 1988;46:292-297.
11. Graça DL. Desmielinização tóxica do sistema nervoso central. II. Aspectos biológicos das células de Schwann observados durante o processo de reparação do tecido. *Arq Neuropsiquiatr* 1989;47:268-273.
12. Graça DL, Blakemore WF. The formation of intracytoplasmic "scrolls" following local injections of ethidium bromide. *Neuropathol Appl Neurobiol* 1985;11:73.
13. Graça DL, Blakemore WF. Delayed remyelination in the rat spinal cord following ethidium bromide injection. *Neuropathol Appl Neurobiol* 1986;12:593-605.
14. Itoyama Y, Webster HF, Richardson EP Jr, Trapp BD. Schwann cell remyelination of demyelinated axons in spinal cord multiple sclerosis lesions. *Ann Neurol* 1983;14:339-346.
15. Kelly WR, Blakemore WF, Jagelman S, Webb S. Demyelination induced in mice by avirulent Semliki Forest virus. II. An ultrastructural study of focal demyelination in the rat brain. *Neuropathol Appl Neurobiol* 1982;8:43-53.
16. Kusaka H, Hirano A, Bornstein MB, Raine CS. Fine structure of astrocytic processes during serum-induced demyelination in vitro. *J Neurol Sci* 1985;69:255-267.
17. Lampert P, Carpenter S. Electron microscopic studies on the vascular permeability and the mechanism of demyelination in the experimental allergic encephalomyelitis. *J Neuropathol Exp Neurol* 1965;24:11-24.
18. Linton HL. Theiler's virus infection in mice: an unusual biphasic disease process leading to demyelination. *Infect Immun* 1975;11:1147-1155.
19. Ludwin SK. Central nervous system demyelination and remyelination in the mouse: an ultrastructural study of cuprizone toxicity. *Lab Invest* 1978;39:597-612.
20. Moore K. Embriologia Clínica Ed3, Rio de Janeiro:Interamericana 1984;354-388.
21. McCarthy GF, Leblond CP. Radioautographic evidence for slow astrocyte turnover and modest oligodendrocyte production in the corpus callosum of adult mice infused with 3H-thymidine. *J Comp Neurol* 1988; 271:589-603.
22. Noble M, Ataliotis P, Barnett SC, Bevan K, Bogler O, Groves A, Jat P, Wolszijk G, Wren D. Development, regeneration, and neoplasia of glia cells in the central nervous system. *Ann NY Acad Sci* 1991;633:35-47.
23. Pereira LAV. Efeitos do brometo de etídio no tronco cerebral de ratos Wistar: aspectos morfológicos relacionados aos processos de desmielinização e remielinização do sistema nervoso central. Tese de Mestrado. Universidade Estadual de Campinas, Campinas, 1994.
24. Pereira LAV, Graça DL. Biologia da neurógliia. *Anais XLII Reunião Anual SBPC* 1990;1:427-429.
25. Pereira LAV, Graça DL, Dertkigil MSJ, Cruz-Höfling MA. Dynamics of remyelination in the brain after exposure to ethidium bromide, 1995. Submitted for publication in *J Neuropathol Appl Neurobiol*.
26. Raff MC, Abney ER, Miller RH. Two glial cell lineages diverge prenatally in the rat optic nerve. *Dev Biol* 1984;106:53-60.
27. Raff MC. Glial cell diversification in the rat optic nerve. *Science* 1989;243:1450-1455.
28. Raine CS. On the occurrence of Schwann cells within the normal central nervous system. *J Neurocytology* 1976;5:371-380.
29. Raine CS. Demyelination diseases. In Davis RL et al (eds). Textbook of neuropathology. Baltimore:Williams & Wilkins, 1985:468-547.
30. Raine CS, Scheinberg L, Waltz JM. Multiple sclerosis: oligodendrocyte survival and proliferation in an active established lesion. *Lab Invest* 1981;45:534-546.
31. Reynolds R, Wilkin GP. Cellular reaction to an acute demyelinating/remyelinating lesion of the rat brain stem: localization of G_{DN} ganglioside immunoreactivity. *J Neurosci Res* 1993;36:405-422.
32. Suzuki K, Zaragoren JC. Degeneration of oligodendroglia in the central nervous system of rats treated with AY9944 or triparanol. *Lab Invest* 1974;31:503-505.
33. Wolszijk G, Noble M. Cooperation between PDGF and FGF converts slowly dividing O-2A^{adult} progenitor cells to rapidly dividing cells with characteristics of O-2A^{perinatal} progenitor cells. *J Cell Biol* 1992;118:889-900.
34. Yajima K, Suzuki K. Demyelination and remyelination in the rat central nervous system following ethidium bromide injection. *Lab Invest* 1979;41:385-392.